tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Tabelecleucel’s Phase 3 EBV+ PTLD Trial Progress Signals Continued Potential for Atara Biotherapeutics
PremiumCompany AnnouncementsTabelecleucel’s Phase 3 EBV+ PTLD Trial Progress Signals Continued Potential for Atara Biotherapeutics
1M ago
Atara Biotherapeutics downgraded to Hold from Buy at Canaccord (earlier)
Premium
The Fly
Atara Biotherapeutics downgraded to Hold from Buy at Canaccord (earlier)
2M ago
FDA Rejects Atara’s EBVALLO BLA, Commercial Path Uncertain
Premium
Company Announcements
FDA Rejects Atara’s EBVALLO BLA, Commercial Path Uncertain
2M ago
Atara Biotherapeutics price target raised to $25 from $17 at Canaccord
PremiumThe FlyAtara Biotherapeutics price target raised to $25 from $17 at Canaccord
2M ago
ATRA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
ATRA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
Atara Biotherapeutics price target raised to $18 from $16 at Mizuho
Premium
The Fly
Atara Biotherapeutics price target raised to $18 from $16 at Mizuho
3M ago
Pierre Fabre announces transfer of BLA for tabelecleucel from Atara Biotherapeutics
PremiumThe FlyPierre Fabre announces transfer of BLA for tabelecleucel from Atara Biotherapeutics
4M ago
Atara Biotherapeutics Announces Significant Workforce Reduction
Premium
Company Announcements
Atara Biotherapeutics Announces Significant Workforce Reduction
5M ago
Atara Biotherapeutics Reduces Board Size, Appoints New Chair
Premium
Company Announcements
Atara Biotherapeutics Reduces Board Size, Appoints New Chair
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100